• Users Online: 291
  • Print this page
  • Email this page
Year : 2019  |  Volume : 2  |  Issue : 1  |  Page : 10-16

Extracellular signal-regulated kinase (ERK) inhibitors in oncology clinical trials

1 Rice University, Denver, CO, USA
2 University of Colorado – Denver, Denver, CO, USA
3 Sarah Cannon Research Institute at HealthONE, Denver, CO, USA

Correspondence Address:
Dr. Gerald S Falchook
Sarah Cannon Research Institute at HealthONE, 1800 Williams Street, Suite 300, Denver, CO 80218
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JIPO.JIPO_17_18

Get Permissions

The mitogen-activated protein kinase (MAPK) pathway consists of the series of protein kinases RAS-RAF-MEK- Extracellular signal-regulated kinase (ERK), and its function is important to cell proliferation, differentiation, motility, and survival. Certain mutations in the pathway, such as KRAS or BRAF V600 mutations are associated with cancer. Inhibitors of this pathway, including some MEK and BRAF inhibitors, are already being used in the clinic, but a variety of selective ERK inhibitors are still being tested in clinical studies. To date, common adverse events associated with ERK inhibitors include diarrhea, nausea, fatigue, and rash. ERK inhibitors have demonstrated preliminary antitumor activity and may be most effective against cancers with RAS, RAF, or MAPK pathway alterations. This review discusses the MAPK pathway, the biological rationale for ERK inhibitors, and clinical trials involving ERK inhibitors.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded380    
    Comments [Add]    
    Cited by others 2    

Recommend this journal